At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
Vicriviroc +1 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Trial to Evaluate the Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC)
In Brief
A Phase 2 clinical trial evaluating Vicriviroc and Pembrolizumab for Colorectal Neoplasms. Completed, enrolled 41 participants across 8 sites in 2 countries.
Detailed Summary
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Neoplasms
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartSep 2018
Primary CompletionJun 2021
TodayJul 2026
First PostedAug 15, 2018
Enrollment StartSep 24, 2018
Primary CompletionJun 8, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 7.9 years ago
Interventions
Vicrivirocdrug
Vicriviroc tablets administered orally, QD at dose level 1 or 2.
Pembrolizumabbiological
Pembrolizumab administered by IV infusion at 200 mg every 3 weeks (Q3W), given on cycle day 1.